Compare Raymond James Financial, Inc. (RJF) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Smith & Nephew plc — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Raymond James Financial, Inc. is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| RJF | SNN | |
|---|---|---|
Market Cap | $33.96B | $11.63B |
Sector | Financials | Health |
52-Week High | $181.18 | $38.53 |
52-Week Low | $140.89 | $27.80 |
Dividend Yield | 1.22% | 2.85% |
Enterprise Value | — | $14.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Recent Q3 2026 results showed record revenues of $3.93 billion, up 16% year-over-year, driven by wealth management growth and investment banking recovery.
RJF presents a compelling investment case with strong fundamentals and analyst support, though technical indicators suggest near-term caution. The consensus price target of $184.11 implies 4.3% upside potential, with no sell ratings among 25 analysts. Key risks include rising expenses and capital markets volatility, while the company's advisor recruitment momentum and dividend payments provide stability.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
